Correspondence
Reversible Posterior Leukoencephalopathy Syndrome and Bevacizumab
N Engl J Med 2006; 354:980-982March 2, 2006
- Article
To the Editor:
We would like to report the occurrence of reversible posterior leukoencephalopathy that we believe is directly attributable to bevacizumab (Avastin), a recombinant, humanized, monoclonal IgG1 antibody that binds and inhibits vascular endothelial growth factor (VEGF). A 59-year-old woman received seven infusions of bevacizumab at two-week intervals for the treatment of metastatic renal cancer, during which time her blood pressure remained within her usual range, at approximately 100/70 mm Hg. Eight days after the last infusion, she presented to the emergency room with severe lethargy. The physical examination was essentially normal except for a blood pressure of 168/88 mm Hg. Laboratory assessment was remarkable only for a white-cell count of 14,000 per cubic millimeter; urinalysis showed more than 100 white cells per high-power field and a moderate number of bacteria. The cerebrospinal fluid was clear, colorless, and acellular, with a total protein level of 78 mg per deciliter and a glucose level of 66 mg per deciliter. The patient was admitted to the hospital after a tonic–clonic seizure in the emergency room that was treated with lorazepam.
The patient's blood pressure initially fluctuated from 156 to 178 mm Hg systolic and from 70 to 98 mm Hg diastolic. Neurologic examination on the first hospital day revealed cortical blindness and extensor plantar responses. Magnetic resonance imaging (MRI) of the brain showed nonenhancing extensive leukoencephalopathy in the subcortical (distal vasculature) distribution (Figure 1Figure 1
MRI Scan of the Brain of a Patient with Leukoencephalopathy.). The patient had a normal brain MRI performed less than two months earlier.The patient made a rapid recovery, despite also having a small, left parieto-occipital hemorrhagic stroke. By hospital day 4, she was alert and able to read regular newsprint at 18 in., and plantar responses reverted to flexor. The blood pressure also returned to normal without treatment. Follow-up MRI six weeks later showed complete resolution of the leukoencephalopathy.
The reversible posterior leukoencephalopathy syndrome (RPLS) was initially reported by Hinchey et al. in 1996.1 We are aware of at least 82 reports in the English literature that associate this syndrome with various conditions, including chemotherapeutic drugs and immunosuppressants.2,3 We have found no reports of association with bevacizumab, which is approved for the treatment of metastatic colon and rectal cancer and is now being assessed in other oncologic settings. Reported adverse effects include hemorrhagic stroke, arterial thrombotic events, hypertension, and the nephrotic syndrome.
Since bevacizumab has a 20-day half-life, we believe this patient's reversible posterior leukoencephalopathy is attributable to bevacizumab. We speculate that this may have resulted from effects of this VEGF inhibitor on the blood–brain barrier. Because of the increasing use of this agent, clinicians should be aware of this potential association.
3 ReferencesPeter Glusker, M.D., Ph.D.
Larry Recht, M.D.
Barton Lane, M.D.
Stanford University Medical Center, Stanford, CA 94305
pglusker@stanfordmed.org 1
Hinchey J ,Chaves C ,Appignani B , et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996;334:494-500
Full Text | Web of Science | Medline2
Garg RK . Posterior leukoencephalopathy syndrome. Postgrad Med J 2001;77:24-28
CrossRef | Web of Science | Medline3
Stott VL ,Hurrell MA ,Anderson TJ . Reversible posterior leukoencephalopathy syndrome: a misnomer reviewed. Intern Med J 2005;35:83-90
CrossRef | Web of Science | Medline
To the Editor:
RPLS is a brain-capillary leak syndrome related to hypertension, fluid retention, and the cytotoxic effects of immunosuppressive agents on the vascular endothelium. Cyclosporine, tacrolimus, granulocyte colony-stimulating factor, cisplatin, epoetin, and immune globulin therapy have been associated with RPLS.1 We report a case of RPLS in association with bevacizumab, a monoclonal antibody directed at VEGF and its receptors.
A 52-year-old woman with hypertension and metastatic rectal adenocarcinoma who had received three cycles of chemotherapy with fluorouracil, leucovorin, and oxaliplatin presented with acute bilateral loss of vision, headache, and confusion 16 hours after her first dose of bevacizumab, which was administered with the fourth cycle of this chemotherapy regimen. The physical examination was unremarkable except for high blood pressure (172/100 mm Hg), hepatomegaly, and bilateral cortical visual loss with normal optic fundi. Laboratory studies, including cerebrospinal fluid and viral analyses, were unrevealing. However, T2-weighted MRI of the brain showed hyperintense areas at the posterior aspects of both occipital lobes. The patient's clinical presentation and imaging findings were characteristic of RPLS. With stringent blood-pressure control, her vision rapidly improved and recovered fully by the third day.
Bevacizumab decreases tumor perfusion, vascular volume, microvascular density, interstitial fluid pressure, and the number of viable, circulating endothelial and progenitor cells and increases the fraction of vessels with pericyte coverage in patients with rectal carcinoma.2 The drug improves survival and the rate of tumor regression in patients with colorectal carcinoma.3 However, bevacizumab-based combination chemotherapy is associated with a risk of grade 3 hypertension in up to 16 percent of patients, possibly secondary to vasospasm.4 Severe hypertensive encephalopathy leads to RPLS and vasogenic edema of the posterior cerebral white matter, induced by endothelial dysfunction and a disrupted blood–brain barrier. We speculate that bevacizumab may have induced vasospasm, which, coupled with hypertension in our patient, led to RPLS.
We suggest that RPLS is an important consideration in patients with poorly controlled hypertension who are treated with VEGF inhibitors. Clinicians should be aware of this potential complication and control blood pressure strictly during and after the bevacizumab infusion. Controlling hypertension and discontinuing the offending agent appear to help reverse this complication. It is important early in the clinical course to differentiate this syndrome from acute cerebral ischemia or thromboembolic phenomena, which are also associated with this agent, in order to avert permanent visual loss.
4 ReferencesCevher Ozcan, M.D.
Stuart J. Wong, M.D.
Parameswaran Hari, M.D.
Medical College of Wisconsin, Milwaukee, WI 53226
phari@mail.mcw. edu 1
Tam CS ,Galanos J ,Seymour JF ,Pitman AG ,Stark RJ ,Prince HM . Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies. Am J Hematol 2004;77:72-76
CrossRef | Web of Science | Medline2
Willett CG ,Boucher Y ,di Tomaso E , et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-147[Erratum, Nat Med 2004;10:649.]
CrossRef | Web of Science | Medline3
Hurwitz H ,Fehrenbacher L ,Novotny W , et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342
Full Text | Web of Science | Medline4
Kabbinavar FF ,Schulz J ,McCleod M , et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005;23:3697-3705
CrossRef | Web of Science | Medline
Author/Editor Response
Genentech is committed to providing physicians and patients with important safety and efficacy information available for bevacizumab (Avastin). Avastin was approved in the United States in February 2004 for use in combination with intravenous fluorouracil chemotherapy for the treatment of newly diagnosed metastatic colorectal cancer. It is also approved in many other countries worldwide, and we estimate that more than 60,000 patients have been treated with Avastin globally.
The letters from Dr. Glusker and colleagues and Dr. Ozcan and colleagues provide valuable information about a very rare syndrome. We agree that the two patients reported meet the clinical criteria for RPLS. At this time, we are reviewing the global safety database to look for cases with clinical signs and symptoms associated with RPLS and are investigating one additional case.
We believe it is important for physicians to be cognizant of the signs and symptoms of this rare but reversible syndrome and its association with even moderate hypertension. Hypertension, a known adverse reaction associated with Avastin treatment, has been included in the Avastin package insert since the drug's approval in 2004. We plan to update the Avastin package insert in the United States to include a description of the syndrome and to recommend discontinuation of Avastin if RPLS is diagnosed. Our corporate partner, Roche, will implement appropriate actions outside of the United States.
Patient safety is of utmost importance to us, and Genentech encourages physicians to continue reporting RPLS and other adverse events observed during Avastin treatment.
Hal Barron, M.D.
Genentech, South San Francisco, CA 94080-4990- Citing Articles (91)
Citing Articles
1
Nicholas A. Butowski, Susan M. Chang. 2012. General and neurological complications of targeted therapy. , 937-945.
CrossRef2
Tali Siegal, Netta Levin. 2012. Infectious, metabolic, and endocrine complications. , 825-851.
CrossRef3
Stephane Ederhy, Hassan Izzedine, Christophe Massard, Ghislaine Dufaitre, Jean Philippe Spano, Gerard Milano, Catherine Meuleman, Benjamin Besse, Franck Boccara, David Kahyat, Ariel Cohen, Jean Charles Soria. (2011) Cardiac side effects of molecular targeted therapies: Towards a better dialogue between oncologists and cardiologists. Critical Reviews in Oncology/Hematology 80:3, 369-379
CrossRef4
Camille Tlemsani, Olivier Mir, Pascaline Boudou-Rouquette, Olivier Huillard, Karin Maley, Stanislas Ropert, Romain Coriat, François Goldwasser. (2011) Posterior reversible encephalopathy syndrome induced by anti-VEGF agents. Targeted Oncology
CrossRef5
Signy Chow, Christina S Cheung, Donald H Lee, Kang Howson-Jan, Anargyros Xenocostas. (2011) Letter to the Editor: Posterior Reversible Encephalopathy Syndrome (PRES) in a Multiple Myeloma Patient Treated with Thalidomide. Leukemia & Lymphoma1-8
CrossRef6
François Goldwasser. (2011) Traitement du cancer colorectal métastatique : une illustration de l’évolution des concepts fondateurs de la cancérologie. La Presse Médicale
CrossRef7
Annick Desjardins, John H. Sampson. (2011) Editorial. Journal of Neurosurgery1-4
CrossRef8
R. C. S. Seet, A. A. Rabinstein. (2011) Clinical features and outcomes of posterior reversible encephalopathy syndrome following bevacizumab treatment. QJM
CrossRef9
Jean-Jacques Mourad, Bernard I. Levy. (2011) Mechanisms of Antiangiogenic-Induced Arterial Hypertension. Current Hypertension Reports 13:4, 289-293
CrossRef10
Laura M. Tormoehlen. (2011) Toxic Leukoencephalopathies. Neurologic Clinics 29:3, 591-605
CrossRef11
Hiroyasu Kaneda, Isamu Okamoto, Taroh Satoh, Kazuhiko Nakagawa. (2011) Reversible posterior leukoencephalopathy syndrome and trastuzumab. Investigational New Drugs
CrossRef12
Yongen Chang, Gilbert Mbeo, Susan J. Littman. (2011) Reversible Posterior Leukoencephalopathy Syndrome Associated with Concurrent Bevacizumab, Gemcitabine, and Oxaliplatin for Cholangiocarcinoma. Journal of Gastrointestinal Cancer
CrossRef13
Renaud Mazeron, Bethany Anderson, Stéphane Supiot, François Paris, Eric Deutsch. (2011) Current state of knowledge regarding the use of antiangiogenic agents with radiation therapy. Cancer Treatment Reviews
CrossRef14
Feng Yang, Chen Jin, Yong-jian Jiang, Ji Li, Yang Di, De-Liang Fu. (2011) Potential role of soluble VEGFR-1 in antiangiogenesis therapy for cancer. Expert Review of Anticancer Therapy 11:4, 541-549
CrossRef15
Derek G. Power, Nancy E. Kemeny. (2011) Nasal septum perforation and bevacizumab. Medical Oncology 28:1, 89-93
CrossRef16
Xavier Bosch, Albert Saiz, Manuel Ramos-Casals. (2011) Monoclonal antibody therapy-associated neurological disorders. Nature Reviews Neurology 7:3, 165-172
CrossRef17
Ursula A Matulonis. (2011) Bevacizumab and its use in epithelial ovarian cancer. Future Oncology 7:3, 365-379
CrossRef18
Carlo C Quattrocchi, Andrea M Alexandre, Giuseppe Tonini, Yuri Errante, Rosario F Grasso, Bruno Zobel. (2011) Brain microischemic phenomena in a woman receiving bevacizumab treatment: a case report. Journal of Medical Case Reports 5:1, 84
CrossRef19
Sharon E. Maynard, S. Ananth Karumanchi. (2011) Angiogenic Factors and Preeclampsia. Seminars in Nephrology 31:1, 33-46
CrossRef20
K Jordan, H H Wolf, W Voigt, T Kegel, L P Mueller, T Behlendorf, C Sippel, D Arnold, H J Schmoll. (2010) Bevacizumab in combination with sequential high-dose chemotherapy in solid cancer, a feasibility study. Bone Marrow Transplantation 45:12, 1704-1709
CrossRef21
Erkan Dogan, Sercan Aksoy, Cagatay Arslan, Didem S. Dede, Kadri Altundag. (2010) Probable sorafenib-induced reversible encephalopathy in a patient with hepatocellular carcinoma. Medical Oncology 27:4, 1436-1437
CrossRef22
Attila Molvarec, Mika Ito, Tomoko Shima, Satoshi Yoneda, Gergely Toldi, Balázs Stenczer, Barna Vásárhelyi, János Rigó, Shigeru Saito. (2010) Decreased proportion of peripheral blood vascular endothelial growth factor–expressing T and natural killer cells in preeclampsia. American Journal of Obstetrics and Gynecology 203:6, 567.e1-567.e8
CrossRef23
Giuseppe Curigliano, Erica L. Mayer, Harold J. Burstein, Eric P. Winer, Aron Goldhirsch. (2010) Cardiac Toxicity From Systemic Cancer Therapy: A Comprehensive Review. Progress in Cardiovascular Diseases 53:2, 94-104
CrossRef24
Denise M. Damek. (2010) Cerebral Edema, Altered Mental Status, Seizures, Acute Stroke, Leptomeningeal Metastases, and Paraneoplastic Syndrome. Hematology/Oncology Clinics of North America 24:3, 515-535
CrossRef25
M. L. Maitland, G. L. Bakris, H. R. Black, H. X. Chen, J. B. Durand, W. J. Elliott, S. P. Ivy, C. V. Leier, J. Lindenfeld, G. Liu, S. C. Remick, R. Steingart, W. H. W. Tang, . (2010) Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors. JNCI Journal of the National Cancer Institute 102:9, 596-604
CrossRef26
Vishal Ranpura, Bhargava Pulipati, David Chu, Xiaolei Zhu, Shenhong Wu. (2010) Increased Risk of High-Grade Hypertension With Bevacizumab in Cancer Patients: A Meta-Analysis. American Journal of Hypertension 23:5, 460-468
CrossRef27
B. K. Kleinschmidt-DeMasters, Denise M. Damek. (2010) The imaging and neuropathological effects of Bevacizumab (Avastin) in patients with leptomeningeal carcinomatosis. Journal of Neuro-Oncology 96:3, 375-384
CrossRef28
C. H. Han, M. P. Findlay. (2010) Chemotherapy-induced reversible posterior leucoencephalopathy syndrome. Internal Medicine Journal 40:2, 153-159
CrossRef29
E. Terwiel, R. Hanrahan, C. Lueck, J. D'Rozario. (2010) Reversible posterior encephalopathy syndrome associated with bortezomib. Internal Medicine Journal 40:1, 69-71
CrossRef30
Marc C. Chamberlain. (2010) 10 Questions About the Use of Bevacizumab in the Management of Recurrent Malignant Gliomas. The Neurologist 16:1, 56-60
CrossRef31
Brett C. Young, Richard J. Levine, S. Ananth Karumanchi. (2010) Pathogenesis of Preeclampsia. Annual Review of Pathology: Mechanisms of Disease 5:1, 173-192
CrossRef32
Kosuke Toda, Naoki Kakihara, Ken Yu, Wataru Ishii, Keigo Yamada, Katsumi Shimomura, Hiroomi Matsumura, Masaharu Ohgaki, Keigo Miyata, Atsushi Takenaka. (2010) Posterior Reversible Encephalopathy Syndrome caused by TS-1 plus Cisplatin Combination Therapy of Advanced Gastric Cancer: Report of a Case. The Japanese Journal of Gastroenterological Surgery 43:4, 365-369
CrossRef33
M. A. Marinella, R. J. Markert. (2009) Reversible posterior leucoencephalopathy syndrome associated with anticancer drugs. Internal Medicine Journal 39:12, 826-834
CrossRef34
Mariëtte HW Kappers, Joep HM van Esch, Stefan Sleijfer, AH Jan Danser, Anton H van den Meiracker. (2009) Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects. Journal of Hypertension 27:12, 2297-2309
CrossRef35
David Schiff, Patrick Y. Wen, Martin J. van den Bent. (2009) Neurological adverse effects caused by cytotoxic and targeted therapies. Nature Reviews Clinical Oncology 6:10, 596-603
CrossRef36
J. -M. Halimi, M. Azizi, G. Bobrie, O. Bouché, G. Deray, G. Guetz, T. Lecomte, B. Levy, J. -J. Mourad, D. Nochy, S. Oudard, P. Rieu, D. Sahali. (2009) Effets vasculaires et rénaux des médicaments anti-angiogéniques: recommandations françaises pour la pratique. Oncologie 11:9-10, 476-489
CrossRef37
Elizabeth L. Strevel, Lillian L. Siu. (2009) Cardiovascular toxicity of molecularly targeted agents. European Journal of Cancer 45, 318-331
CrossRef38
Helen X. Chen, Jessica N. Cleck. (2009) Adverse effects of anticancer agents that target the VEGF pathway. Nature Reviews Clinical Oncology 6:8, 465-477
CrossRef39
Kelly L. Snider, Michael L. Maitland. (2009) Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors. Targeted Oncology 4:2, 67-76
CrossRef40
Dale R Shepard, Jorge A Garcia. (2009) Toxicity associated with the long-term use of targeted therapies in patients with advanced renal cell carcinoma. Expert Review of Anticancer Therapy 9:6, 795-805
CrossRef41
Nasim Afsar-Manesh, Neveen El-Farra, Molly Billings, Michael Lazarus. (2009) PRESsed for time. Journal of Hospital Medicine 4:5, 321-322
CrossRef42
Carolyn Fein Levy, Khine Zin Oo, Fernando Fireman, Louisdon Pierre, Marita A. Bania, Swayamprabha Sadanandan, Darrell J. Yamashiro, Julia L. Glade Bender. (2009) Reversible posterior leukoencephalopathy syndrome in a child treated with bevacizumab. Pediatric Blood & Cancer 52:5, 669-671
CrossRef43
Denise M. Damek. (2009) Cerebral Edema, Altered Mental Status, Seizures, Acute Stroke, Leptomeningeal Metastases, and Paraneoplastic Syndrome. Emergency Medicine Clinics of North America 27:2, 209-229
CrossRef44
H. Izzedine, S. Ederhy, F. Goldwasser, J. C. Soria, G. Milano, A. Cohen, D. Khayat, J. P. Spano. (2009) Management of hypertension in angiogenesis inhibitor-treated patients. Annals of Oncology 20:5, 807-815
CrossRef45
C. Chevreau. (2009) Les effets secondaires des anti-angiogéniques (à l’exception des effets cutanés). Oncologie 11:5, 285-290
CrossRef46
Cathy Eng. (2009) Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer. Nature Reviews Clinical Oncology 6:4, 207-218
CrossRef47
Cabot, Richard C.Harris, Nancy Lee, Shepard, Jo-Anne O., Rosenberg, Eric S., Cort, Alice M., Ebeling, Sally H.Peters, Christine C., Singhal, Aneesh B., Kimberly, W. Taylor, Schaefer, Pamela W., Hedley-Whyte, E. Tessa, . (2009) Case 8-2009. New England Journal of Medicine 360:11, 1126-1137
Full Text48
Chun Lam, S. Ananth Karumanchi. 2009. Pregnancy and the Kidney. , 483-513.
CrossRef49
Tamara Majic, Venkatesh Aiyagari. (2008) Cerebrovascular Manifestations of Pheochromocytoma and the Implications of a Missed Diagnosis. Neurocritical Care 9:3, 378-381
CrossRef50
David R Fogelman, Scott Kopetz, Cathy Eng. (2008) Emerging drugs for colorectal cancer. Expert Opinion on Emerging Drugs 13:4, 629-642
CrossRef51
Jörg Dietrich, Andrew D Norden, Patrick Y Wen. (2008) Emerging antiangiogenic treatments for gliomas – efficacy and safety issues. Current Opinion in Neurology 21:6, 736-744
CrossRef52
Jose L. Mauriz, Javier González-Gallego. (2008) Antiangiogenic drugs: Current knowledge and new approaches to cancer therapy. Journal of Pharmaceutical Sciences 97:10, 4129-4154
CrossRef53
Anne H. Blaes, Karen S. Santa-Cruz, Chung K.K. Lee, Susanta K. Hui, Bruce A. Peterson. (2008) Necrotizing leukoencephalopathy following CHOP chemotherapy. Leukemia Research 32:10, 1611-1614
CrossRef54
Grace K. Dy, Alex A. Adjei. (2008) Systemic cancer therapy: Evolution over the last 60 years. Cancer 113:S7, 1857-1887
CrossRef55
Stephane Legriel, Fabrice Bruneel, Odile Spreux-Varoquaux, Aurelie Birenbaum, Marie Laure Chadenat, François Mignon, Nathalie Abbosh, Matthieu Henry-Lagarrigue, Laure Revault D’Allonnes, Pierre Guezennec, Gilles Troche, Jean Pierre Bedos. (2008) Lysergic Acid Amide-Induced Posterior Reversible Encephalopathy Syndrome with Status Epilepticus. Neurocritical Care 9:2, 247-252
CrossRef56
Bhawna Sirohi, Katy Smith. (2008) Bevacizumab in the treatment of breast cancer. Expert Review of Anticancer Therapy 8:10, 1559-1568
CrossRef57
Mohanraj Dhanabal, S. Ananth Karumanchi, Vikas P. Sukhatme. (2008) Targeting tumor vascular endothelium: an emerging concept for cancer therapy. Drug Development Research 69:6, 340-351
CrossRef58
Miriam Koopman, Erik W. Muller, Cornelis J. A. Punt. (2008) Reversible Posterior Leukoencephalopathy Syndrome Caused by Bevacizumab: Report of a Case. Diseases of the Colon & Rectum 51:9, 1425-1426
CrossRef59
S. Ananth Karumanchi, Marshall D. Lindheimer. (2008) Advances in the understanding of eclampsia. Current Hypertension Reports 10:4, 305-312
CrossRef60
Lynn Feun, Niramol Savaraj. (2008) Topoisomerase I inhibitors for the treatment of brain tumors. Expert Review of Anticancer Therapy 8:5, 707-716
CrossRef61
Brian M. Wolpin, Robert J. Mayer. (2008) Systemic Treatment of Colorectal Cancer. Gastroenterology 134:5, 1296-1310.e1
CrossRef62
Franck Bürki, Kattalin Badie, Philippe Bartoli, Pascale Bernard, Jean Louis Montastruc, Haleh Bagheri. (2008) Reversible posterior leukoencephalopathy syndrome associated with bevacizumab/doxorubicin regimen. British Journal of Clinical Pharmacology 65:5, 793-794
CrossRef63
Teri N. Kreisl. (2008) Neurologic complications of antitumor antibody therapies. Current Neurology and Neuroscience Reports 8:3, 259-263
CrossRef64
Sajeel Chowdhary, Eric T Wong. (2008) Bevacizumab combined with irinotecan for recurrent glioblastoma multiforme—improvement over available therapy?. Nature Clinical Practice Neurology 4:5, 242-243
CrossRef65
Jair Bar, Amir Onn. (2008) Combined anti-proliferative and anti-angiogenic strategies for cancer. Expert Opinion on Pharmacotherapy 9:5, 701-715
CrossRef66
W.S. Bartynski, H.P. Tan, J.F. Boardman, R. Shapiro, J.W. Marsh. (2008) Posterior Reversible Encephalopathy Syndrome after Solid Organ Transplantation. American Journal of Neuroradiology 29:5, 924-930
CrossRef67
A. S.R. Maharaj, T. E. Walshe, M. Saint-Geniez, S. Venkatesha, A. E. Maldonado, N. C. Himes, K. S. Matharu, S. A. Karumanchi, P. A. D'Amore. (2008) VEGF and TGF- are required for the maintenance of the choroid plexus and ependyma. Journal of Experimental Medicine 205:2, 491-501
CrossRef68
David A. Reardon, Annick Desjardins, Jeremy N. Rich, James J. Vredenburgh. (2008) The Emerging Role of Anti-Angiogenic Therapy for Malignant Glioma†. Current Treatment Options in Oncology 9:1, 1-22
CrossRef69
George Kannarkat, Erin E Lasher, David Schiff. (2008) Neurologic complications of chemotherapy agents. Current Opinion in Internal Medicine 7:1, 88-94
CrossRef70
Sharon Maynard, Franklin H. Epstein, S. Ananth Karumanchi. (2008) Preeclampsia and Angiogenic Imbalance. Annual Review of Medicine 59:1, 61-78
CrossRef71
G. Maalouf, E. Mitry, A. Lacout, A. Lièvre, P. Rougier. (2008) Isolated brainstem involvement in posterior reversible leukoencephalopathy induced by bevacizumab. Journal of Neurology 255:2, 295-296
CrossRef72
Silvia Peter, Norbert Hausmann, Antonius Schuster, Hubert Friedrich Boehm. (2008) Reversible posterior leukoencephalopathy syndrome and intravenous bevacizumab. Clinical & Experimental Ophthalmology 36:1, 94-96
CrossRef73
Christopher Vaughn, Louann Zhang, David Schiff. (2008) Reversible posterior leukoencephalopathy syndrome in cancer. Current Oncology Reports 10:1, 86-91
CrossRef74
Jai Grewal, Harpreet K. Grewal, Arthur D. Forman. (2008) Seizures and epilepsy in cancer: Etiologies, evaluation, and management. Current Oncology Reports 10:1, 63-71
CrossRef75
Femke Hillen, Arjan W. Griffioen. (2007) Tumour vascularization: sprouting angiogenesis and beyond. Cancer and Metastasis Reviews 26:3-4, 489-502
CrossRef76
Hernan D. Kopcow, S. Ananth Karumanchi. (2007) Angiogenic factors and natural killer (NK) cells in the pathogenesis of preeclampsia. Journal of Reproductive Immunology 76:1-2, 23-29
CrossRef77
Farheen M. Shah-Khan, Daryl Pinedo, Prabodh Shah. (2007) Reversible posterior leukoencephalopathy syndrome and anti-neoplastic agents: a review. Oncology Reviews 1:3, 152-161
CrossRef78
Uwe Dietrich, Rainer Borgstedt, Frank Herrmann, Friedhelm Bach. (2007) Das Posteriore Reversible Enzephalopathie-Syndrom (PRES). Intensivmedizin und Notfallmedizin 44:7, 409-415
CrossRef79
Arindel S.R. Maharaj, Patricia A. D'Amore. (2007) Roles for VEGF in the adult. Microvascular Research 74:2-3, 100-113
CrossRef80
Sasja F. Mulder, Cornelis J.A. Punt. (2007) Managing toxicities of targeted therapies. European Journal of Cancer Supplements 5:5, 394-397
CrossRef81
Jacques Medioni, Oana Cojocarasu, Eugeniu Banu, Alexia Cassar-Queudeville, Philippe Halimi, Stéphane Oudard. (2007) Reversible encephalopathy syndrome secondary to sunitinib for metastatic renal cell carcinoma patient. Targeted Oncology 2:3, 193-195
CrossRef82
Roisin M. Connolly, Colin P. Doherty, Peter Beddy, Ken O’Byrne. (2007) Chemotherapy induced reversible posterior leukoencephalopathy syndrome. Lung Cancer 56:3, 459-463
CrossRef83
Henk. M. W. Verheul, Herbert M. Pinedo. (2007) Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nature Reviews Cancer 7:6, 475-485
CrossRef84
Stephan Michels, Franz Prager, Sophie J Bakri, Joachim Wachtlin. (2007) Bevacizumab for ophthalmic diseases. Expert Review of Ophthalmology 2:3, 369-378
CrossRef85
S A Karumanchi, F H Epstein. (2007) Placental ischemia and soluble fms-like tyrosine kinase 1: Cause or consequence of preeclampsia?. Kidney International 71:10, 959-961
CrossRef86
Jeffrey C Cilley, Keren Barfi, Al B Benson, Mary F Mulcahy. (2007) Bevacizumab in the treatment of colorectal cancer. Expert Opinion on Biological Therapy 7:5, 739-749
CrossRef87
Roy L Pañares, Agustin A Garcia. (2007) Bevacizumab in the management of solid tumors. Expert Review of Anticancer Therapy 7:4, 433-445
CrossRef88
Andrew D. Norden, Tracy T. Batchelor. (2007) Reversible Posterior Leukoencephalopathy Syndrome. Onkologie 30:3, 90-91
CrossRef89
Levine, Richard J., Lam, Chun, Qian, Cong, Yu, Kai F., Maynard, Sharon E., Sachs, Benjamin P., Sibai, Baha M., Epstein, Franklin H., Romero, Roberto, Thadhani, Ravi, Karumanchi, S. Ananth, . (2006) Soluble Endoglin and Other Circulating Antiangiogenic Factors in Preeclampsia. New England Journal of Medicine 355:10, 992-1005
Full Text90
(2006) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 15:8, i-xii
CrossRef91
F. Ziemssen, K. U. Bartz-Schmidt, S. Grisanti. (2006) (Neben-) Wirkungen der VEGF-Inhibition. Der Ophthalmologe 103:6, 484-492
CrossRef
